TNF and cancer: In this randomized, open-label, noninferiority trial, Ytterberg and colleagues demonstrated that the incidence of cancer was higher among patients exposed to tofacitinib compared to those receiving TNF-α inhibitors, with an HR of 1.48 (95% CI: 1.04–2.09) [25].